Moberg Pharma Acquires OTC Brands from Bayer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moberg Pharma Acquires OTC Brands from Bayer



Moberg Pharma AB, a Swedish pharmaceutical company,  has signed a deal to acquire three over-the-coutner brands in the US from Bayer HealthCare. The acquired portfolio includes: Domeboro, a topical astringent used for relieving itch and minor skin irritations; Vanquish, an internal analgesic; and Fergon, an iron supplement. The brands will be sold through Moberg’s current channel, primarily in chain drugstores and mass retailers, such as Walmart. The transaction is expected to close before the end of 2013.

Source: Moberg Pharma

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here